The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Investigating the Movement of Intravitreal Human Serum Albumin Nanoparticles in the Vitreous and Retina
Abstract
Purpose To investigate the movement of intravitreally injected human serum albumin nanoparticles (HSA-NP) with respect to nanoparticle surface charge and retinal injury.Methods HSA-NPs were developed by a desolvation technique. HSA-NPs were cationized by covalent coupling of hexamethylenediamine on the particle surface. Either anionic or cationic HSA-NPs were injected to determine the effect of surface charge on intravitreal nanoparticle movement. HSA-NPs were injected intravitreally into both normal and laser photocoagulated eyes to examine the effect of the integrity of retinal tissue on the retinal penetration. The retinal penetration of fluorescence labeled anionic HSA-NPs was investigated by confocal microscopy.Results Anionic particles (-33.3+/-6.1 mV) more easily diffused through the 3-dimensional vitreal network of collagen fibrils than did their cationic counterparts (11.7+/-7.2 mV). In the laser photocoagulated retina, more HSA-NPs were detected in the choroidal space, compared to the normal retina. The immunohistochemical studies indicated that HSA-NPs were taken up into Müller cells.Conclusions The movement of intravitreal nanoparticles depended on both nanoparticles surface charge and retinal injury. The Müller cells might play an important role in the retinal penetration of nanoparticles. The anionic HSA-NP is a promising drug or gene delivery carrier to the sub-retinal space and RPE.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies such as PEGylation [271], charge modification [272], and coating with hyaluronate or chloroquine [273,274] have been shown to improve retinal transduction in animal models when administered intravitreally.”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [272]
Citations
Cites
(1984) · PubMed · Cited by 1,200
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 965
Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Jonas, J. B. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.1.57 · Cited by 567
Nanotechnology in ocular drug delivery
Sahoo, S. K., Dilnawaz, F., & Krishnakumar, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.021 · Cited by 554
Nanotechnology in Ocular Drug Delivery
Patel, D. H., Pathak, D., & Giradkar, P. (2021) · Springer eBooks · doi:10.1007/978-981-33-4497-6_18 · Cited by 362
Bourges, J., Gautier, S., Delié, F., Bejjani, R. A., Jeanny, J., Gurny, R., BenEzra, D., & Béhar‐Cohen, F. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1068 · Cited by 357
Ruponen, M., Ylä‐Herttuala, S., & Urtti, A. O. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(98)00199-0 · Cited by 352
Drug delivery for posterior segment eye disease.
Geroski, D. H., & Edelhauser, H. F. (2000) · PubMed · Cited by 341
Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery
Lü, W., Zhang, Y., Tan, Y., Hu, K., Jiang, X., & Fu, S. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.027 · Cited by 317
Cited by
Sorted by citations
Items 101–174 of 174
Waldstein, S. M., Montuoro, A., Podkowinski, D., Philip, A.-M., Gerendas, B. S., Bogunović, H., & Schmidt-Erfurth, U. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-02971-y · Cited by 25
Kurosaki, T., Uematsu, M., Shimoda, K., Suzuma, K., Nakai, M., Nakamura, T., Kitahara, T., Kitaoka, T., & Sasaki, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00728 · Cited by 24
Zhang, Y., Watson, S. L., Ramaswamy, Y., & Singh, G. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103200 · Cited by 25
Therapeutics and Carriers: The Dual Role of Proteins in Nanoparticles for Ocular Delivery
Pescina, S., Sonvico, F., Santi, P., & Nicoli, S. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150108150217 · Cited by 21
Arta, A., Eriksen, A. Z., Melander, F., Kempen, P. J., Larsen, M., Andresen, T. L., & Urquhart, A. J. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-23800 · Cited by 22
Gebhardt, C., Lehmann, M., Reif, M., Zacharias, M., Gemmecker, G., & Cordes, T. (2021) · ChemPhysChem · doi:10.1002/cphc.202100509 · Cited by 20
Mucoadhesive Polymers for Enhancing Retention in Ocular Drug Delivery
Khare, A., Grover, K., Pawar, P. K., & Singh, I. (2015) · Wiley eBooks · doi:10.1002/9781119162346.ch13 · Cited by 18
Determining vitreous viscosity using fluorescence recovery after photobleaching
Srikantha, N., Gonzalez, Y. T., Simpson, A. R. H., Elsaid, N., Somavarapu, S., Suhling, K., & Jackson, T. L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261925 · Cited by 18
Christensen, G., Urimi, D., Lorenzo‐Soler, L., Schipper, N. G. M., & Paquet‐Durand, F. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.04.012 · Cited by 18
Nanoparticle‐motivated gene delivery for ophthalmic application
Mitra, R. N., Zheng, M., & Han, Z. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1356 · Cited by 18
Nanoparticle-based optical interfaces for retinal neuromodulation: a review
Stoddart, P. R., Begeng, J. M., Tong, W., Ibbotson, M. R., & Kameneva, T. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1360870 · Cited by 18
Xue, R., Wu, H., Li, S., Pu, N., Wei, D., Zhao, N. R., Cui, Y., Li, H., Song, Z., & Tao, Y. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101126 · Cited by 19
Wong, L., Hirst, S. M., Pye, Q. N., Reilly, C. M., Seal, S., & McGinnis, J. F. (2013) · PLoS ONE · doi:10.1371/annotation/569989ba-586e-468d-bba3-d9a737b15459 · Cited by 17
Sung, M. S., Moon, M. J., Thomas, R. G., Kim, S. Y., Lee, J. S., Jeong, Y. Y., Park, I., & Park, S. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239297 · Cited by 16
Melgar-Asensio, I., Kandela, I. K., Aird, F., Darjatmoko, S. R., Rı́os, C. D. L., Sorenson, C. M., Albert, D. M., Sheibani, N., & Henkin, J. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-24087 · Cited by 16
You, S., Kim, H.-T., Jung, H., Kim, B., Lee, E. J., Kim, J. W., & Kim, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120188 · Cited by 15
Self-citationMicro/Nanoparticle Delivery Systems for Ocular Diseases
Halasz, K., Kelly, S. J., Iqbal, M. T., Pathak, Y. V., & Sutariya, V. B. (2019) · Assay and Drug Development Technologies · doi:10.1089/adt.2018.911 · Cited by 15
The EyeFlowCell: Development of a 3D-Printed Dissolution Test Setup for Intravitreal Dosage Forms
Auel, T., Großmann, L., Schulig, L., Weitschies, W., & Seidlitz, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091394 · Cited by 14
Charge-Converting Nanoemulsions as Promising Retinal Drug and Gene Delivery Systems
Le, N. N., Zsák, S., Le‐Vinh, B., Friedl, J. D., Kali, G., Knoll, P., Seitter, H., Koschak, A., & Bernkop‐Schnürch, A. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c11649 · Cited by 14
Drug-loaded nanocarriers for back-of-the-eye diseases- formulation limitations
Hamdi, Y., Lallemand, F., & Benita, S. (2015) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.09.010 · Cited by 14
Nanoparticulate Transscleral Ocular Drug Delivery
Shah, J. (2014) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.1000116 · Cited by 14
Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers
Li, H., Liu, W., Sorenson, C. M., Sheibani, N., Albert, D. M., Senanayake, T. H., Vinogradov, S. V., Henkin, J., & Zhang, H. F. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22160 · Cited by 14
Qian, K., Wu, J., Zhang, E.-Q., Zhang, Y.-G., & Fu, A. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s83731 · Cited by 14
Differential Vitreous Dye Diffusion Following Microplasmin or Plasmin Pre-Treatment
Elkareem, A. M. G., Willikens, B., Stassen, J. M., & de Smet, M. D. (2010) · Current Eye Research · doi:10.3109/02713680903484259 · Cited by 13
Hatamie, S., Shih, P., Chen, B., Wang, I., Young, T., & Yao, D. (2020) · Nanomaterials · doi:10.3390/nano10122555 · Cited by 13
Therapies in Development for Non-Infectious Uveitis
Sadiq, M. A., Agarwal, A. K., Hassan, M., Afridi, R., Sarwar, S., Soliman, M. K., Diana, V., & Nguyen, Q. D. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150731103847 · Cited by 13
Balasso, A., Subrizi, A., Salmaso, S., Mastrotto, F., Garofalo, M., Tang, M., Chen, M., Xu, H., Urtti, A. O., & Caliceti, P. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105785 · Cited by 13
Ophthalmic dosage forms for drug delivery to posterior segment
Lee, J., & Rhee, Y.-S. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00554-8 · Cited by 13
Vitreous and Vitreoretinal Interface
Sebag, J., & Green, W. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00021-7 · Cited by 12
Clerck, K. D., Smedt, S. C. D., Remaut, K., & Peynshaert, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113849 · Cited by 11
Application of Nanomaterials in the Treatment and Diagnosis of Ophthalmology Diseases
Liu, N., Wu, Q., Liu, Y., Li, J., Ji, P., & Fu, G. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666200210104449 · Cited by 10
Gogoi, N. R., Marbaniang, D., Pal, P., Ray, S., & Mazumder, B. (2022) · Pharmaceutical Nanotechnology · doi:10.2174/2211738510666220806102612 · Cited by 10
Nanoparticles in the Treatment of Angiogenesis-Related Blindness
Jo, D. H., Kim, J. H., Lee, T. G., & Kim, J. H. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0113 · Cited by 9
Pyruvate-conjugation of PEGylated liposomes for targeted drug delivery to retinal photoreceptors
Christensen, G., Chen, Y., Urimi, D., Zizmare, L., Trautwein, C., Schipper, N. G. M., & Paquet‐Durand, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114717 · Cited by 9
The Promise of Nanomedicine for Ocular Disease
Thomson, H. A., & Lotery, A. J. (2009) · Nanomedicine · doi:10.2217/nnm.09.43 · Cited by 9
Nanoengineered biomaterials for retinal repair
Patel, B. B., Sharma, A. D., Mammadova, N., Sandquist, E. J., Uz, M., Mallapragada, S. K., & Sakaguchi, D. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813355-2.00010-7 · Cited by 8
Dąbkowska, M., Stukan, I., Kosiorowska, A., Szatanik, A., Łuczkowska, K., Machalińska, A., & Machaliński, B. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130726 · Cited by 8
Lim, Y., Campochiaro, P. A., & Green, J. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.010 · Cited by 9
Pillay, V., Choonara, Y. E., & du Toit, L. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2_18 · Cited by 8
Active Transport and Ocular Distribution of Intravitreally Injected Liposomes
Eriksen, A. Z., Melander, F., Eriksen, G. D. M., Kempen, P. J., Kjær, A., Andresen, T. L., & Urquhart, A. J. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.8.20 · Cited by 7
Tasharrofi, N., Kouhkan, F., Soleimani, M., Soheili, Z., Atyabi, F., Javar, H. A., & Dorkoosh, F. A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.12.048 · Cited by 7
Nance, E. A., & McKenna, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816662-8.00007-2 · Cited by 7
OCULAR DRUG DELIVERY SYSTEMS: A REVIEW
Macovei, L. (2021) · FARMACIA · doi:10.31925/farmacia.2021.6.2 · Cited by 7
Breaking the ocular barrier through nano-lipid carriers to treat intraocular diseases
Giri, S., Badwaik, H. R., & Giri, T. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104867 · Cited by 5
Cattaneo, A. G., Gornati, R., Bernardini, G., Sabbioni, E., Manzo, L., & Gioacchino, M. D. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch13 · Cited by 5
In vitro model of retinal pigment epithelium for use in drug delivery studies
Mannermaa, E. (2010) · UEF eRepo (University of Eastern Finland) · Cited by 5
Chitosan-Based Gels for Ocular Drug Delivery
Islam, M. M., Biswas, S., Islam, M. S., Shahruzzaman, M., Hasan, M. M., Islam, M. D., Haque, P., & Rahman, M. M. (2022) · Springer eBooks · doi:10.1007/978-981-16-4787-1_9 · Cited by 4
Novel Biomaterials Based Strategies for Neurodegeneration: Recent Advancements and Future Prospects
Singh, D., & Nagdev, S. A. (2024) · Current Drug Delivery · doi:10.2174/0115672018275382231215063052 · Cited by 4
A single molecule carrier for ocular posterior segment diseases
Zhang, X., Yue, Y., Yang, Y., Ying, A., Ma, R., Chen, J., Chen, F., Hou, X.-Y., Pan, Y., Ren, D.-Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.052 · Cited by 4
Endogenous Polymers as Biomaterials for Nanoparticulate Gene Therapy
Zorzi, G. K., Seijo, B., & Sánchez, A. (2015) · doi:10.1002/9781119041375.ch8 · Cited by 4
Xu, L., Chen, Z.-A., Wu, C.-H., Chen, Y., Wu, S., Mou, C., Tseng, C., Chien, Y., Chan, H. W.-H., Yang, T., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107398 · Cited by 3
Ophthalmic Nanosuspensions: Toxicity and Formulation
Patel, P., Grover, A., Hirani, A., Lee, Y. W., & Pathak, Y. V. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2_20 · Cited by 3
Nanomedicine-Based Delivery to the Posterior Segment of the Eye: Brighter Tomorrow
Jalil, A., Kanwar, R. K., Pathak, Y. V., Mohammedawi, M. A., & Kanwar, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_11 · Cited by 3
Tian, Z., Yang, J., Jiang, X., Ma, J., Li, N., Zhang, J., Huang, J., Liu, H., Chen, Y., & Qian, F. (2025) · Small · doi:10.1002/smll.202507170 · Cited by 2
Nanoparticles for drug delivery targeting neurodegeneration in brain and eye
Teng, F., Huang, X., Ni, R., Suen, W. L. L., & Chau, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816505-8.00006-0 · Cited by 2
Nanotechnology and Nanoparticles
Durazo, S. A., & Kompella, U. B. (2011) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4419-9920-7_11 · Cited by 2
An overview of novel formulations for ocular viral infections: focused on nanomedicines
Verma, S., Nainwal, N., & Juyal, D. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2515998 · Cited by 1
Nucleic acid drug delivery in ophthalmology: Emerging trends and future perspectives
Yang, H., Zuo, J., Lv, S., Wei, X., Pan, M., Zhu, Z., Wang, Y., Jie, Y., Lu, Z., & Zhang, X. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114729 · Cited by 1
Gardikiotis, F. A., Peptu, C. A., Popa, M., & Costin, D. (2011) · Romanian Neurosurgery · Cited by 1
Colloidal Carriers in Ophthalmic Drug Delivery
Gupta, D. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2_15 · Cited by 1
Nano/Microparticles for Retina and Posterior Diseases
Patel, A., Patel, J. K., & Beit‐Yannai, E. (2018) · Springer eBooks · doi:10.1007/978-3-319-95807-1_7 · Cited by 1
Gene Therapy in the Treatment of Geographic Atrophy
Csaky, K. G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000387 · Cited by 1
Self-citationManagement of Vitreomacular Traction
Mishra, K., & Scott, A. W. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_104 · Cited by 1
Giuliari, G. P., Bracha, P., Sperry, A. B., & Ciulla, T. A. (2019) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-3-030-25886-3_10 · Cited by 1
Double Emulsion Mucoadhesive Nanoparticles for Hydrophilic Ocular Drug Delivery
Bahsoun, N. E.-H. (2018) · UWSpace (University of Waterloo) · Cited by 1
Enzyme-functionalized microparticles to open the vitreoretinal interfacePreprint
Motyčková, L., Peter, F., Geisweid, L., Junker, N., Pérez-Serrano, M. I. R. D. A., Tabarova, M., Curticean, R., Wacker, I. U., Schröder, R. R., Hammer, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.12.699029 · Cited by 1
Magnetic nanoparticles as intraocular drug delivery system to target Retinal Pigmented Epithelium
Giannaccini, M., Giannini, M., Calatayud, M. P., Goya, G. F., Cuschieri, A., Dente, L., & Vittoria, R. (2014) · CINECA IRIS Institutial research information system (University of Pisa)
Computer Vision Algorithm Development and Biomedical Applications
Kearney, V. P. (2016) · UTA ResearchCommons (University of Texas Arlington)
Omerović, N., & Vranić, E. (2021) · Global Journal of Medical Research · doi:10.34257/gjmrbvol21is3pg9
Christensen, G., Chen, Y., Urimi, D., Schipper, N. G. M., & Paquet‐Durand, F. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.18.517040
Formulation/design concepts based on the features/barriers of ocular drug deliveries
Orasugh, J. T., Chattopadhyay, D., Ray, S. S., & Adhikari, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99156-8.00007-1
Ocular drug delivery systems and nanotechnology
Dubey, S. (2025) · IP International Journal of Ocular Oncology and Oculoplasty · doi:10.18231/j.ijooo.2024.034
Hamedani, Y. P., Hurst, J., Ritter, M. U., Weingarten, P., Skokowa, J., Schnichels, S., & Adams, F. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202500788
Zheng, Z., Rong, G., Li, G., Zhai, Y., Liang, Y., Shi, M., Huang, J., Zhang, Y., Zhao, X., Zhuo, Q., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103492
Metadata
- Authors
- Kim, H., Robinson, S. B., & Csaky, K. G.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Kim, Hyuncheol
- Venue
- Pharmaceutical Research
- Published
- 2008-10-29
- Volume
- 26
- Issue
- 2
- Pages
- 329-337
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2026741029
- Cited by
- 174
- References
- 38
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 13 · 2021: 15 · 2020: 9 · 2019: 14 · 2018: 15 · 2017: 15 · 2016: 9 · 2015: 14 · 2014: 10 · 2013: 9 · 2012: 5
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- human serum albumin nanoparticles, intravitreal injection, vitreous humor, surface charge, cationic nanoparticles, anionic nanoparticles, laser photocoagulation, retinal damage, Müller cells, choroid, retinal pigment epithelium
- MeSH terms
- Animals, Choroid, Diamines, Diffusion, Drug Carriers, Fluorescent Dyes, Humans, Immunohistochemistry, Particle Size, Retina, Serum Albumin, Surface Properties, Vitreous Body, Bruch Membrane, Microscopy, Confocal, Rats, Laser Therapy, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review